Experimental cancer drug TAK-500 tested in 61 patients – trial halted early
NCT ID NCT05070247
First seen Jan 24, 2026 · Last updated Jun 22, 2026 · Updated 19 times
Summary
This study tested a new drug called TAK-500, given alone or with another immunotherapy (pembrolizumab), in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The goal was to check safety and see if the drug could shrink tumors. The trial was terminated early, so results are limited, but researchers were looking for side effects and signs of tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
New York University
New York, New York, 10016-4744, United States
-
Northwestern
Chicago, Illinois, 60611, United States
-
START South Texas Accelerated Research Therapeutics
San Antonio, Texas, 78229, United States
-
Sarah Cannon Cancer Institute
Nashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute
Denver, Colorado, 80218, United States
-
Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
Univeristy of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of California San Diego
La Jolla, California, 92093, United States
-
University of Colorado - Anschutz Medical Campus - PPDS
Aurora, Colorado, 80045, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TAK-500 (a drug that activates the immune system) and pembrolizumab (an immunotherapy)
What this could lead to
If it works, this could point toward a new treatment option for several advanced cancers that have stopped responding to standard therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) that was terminated, so results are limited. The drug may cause significant side effects, and its effectiveness is not yet proven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.